During the quarter ended March 31, 2025, the Company determined that a sustained decrease in its stock price that occurred during that quarter indicated that the carrying values of its goodwill and other long-lived assets may not be recoverable. Additional factors that contributed to this conclusion were the Company’s recent operating results, liquidity risk and the macroeconomic conditions then impacting the life sciences industry. Based on this determination, the Company performed an interim quantitative impairment test on its goodwill and other long-lived assets as of March 31, 2025 and determined that the carrying value of the reporting unit exceeded its fair value by $48.0 million. Accordingly, the Company recorded such amount as a goodwill impairment charge for the three months ended March 31, 2025.

During the quarter ended March 31, 2026, the Company’s decision in January 2026 to initiate the Project Viking restructuring plan was determined to be a triggering event indicating that the carrying values of its goodwill and other long-lived assets may not be recoverable. Based on its quantitative goodwill impairment test and recoverability assessment of long-lived assets, the Company determined that there was no impairment of its goodwill and other long-lived assets as of March 31, 2026.

The change in the carrying amount of goodwill for the three months ended March 31, 2026 was as follows:

Intangible assets, net at March 31, 2026 and December 31, 2025 consisted of the following:

Intangible asset amortization expense for the three months ended March 31, 2026 and 2025 was as follows:

As of March 31, 2026, estimated future amortization expense of amortizable intangible assets is as follows: